- Nine months versus 12 months of adjuvant trastuzumab for patients with HER2-positive breast cancer
-
El-Enbaby , El Moneim , El atti Khedr GA, Elwany YM
- KMID: 2432608
- Korean J Clin Oncol.
- 2018 Dec;14(2):108-115.
- doi: 10.14216/kjco.18019
PURPOSE: This study aimed to compare the results of treatment with adjuvant trastuzumab for 9 months versus 12 months in human epidermal growth factor 2 (HER2)-positive breast cancer patients. The... -
- CITED
-
- Close
- SHARE
-
- Close
